My bibliography
Save this item
The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing
Citations
Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- M4A Would Deliver Authoritarian, Unaffordable, Low-Quality Care
by Michael F. Cannon in Cato Unbound on 2020-04-06 10:25:00
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2024.
"The Economics of the Public Option: Evidence from Local Pharmaceutical Markets,"
American Economic Review, American Economic Association, vol. 114(3), pages 615-644, March.
- Juan Pablo Atala & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2021. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Documentos de Trabajo 561, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2023. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Working Papers 951, Queen Mary University of London, School of Economics and Finance.
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2022. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," NBER Working Papers 30779, National Bureau of Economic Research, Inc.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2021. "The Economics of the Public Option:Evidence from Local Pharmaceutical Markets," PIER Working Paper Archive 21-012, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Juan-José Ganuza & Gerard Llobet & Beatriz Domínguez, 2009.
"R& D in the Pharmaceutical Industry: A World of Small Innovations,"
Management Science, INFORMS, vol. 55(4), pages 539-551, April.
- Beatriz Domínguez & Juan José Ganuza & Gerard Llobet, 2005. "R&D in the pharmaceutical industry: A world of small innovations," Economics Working Papers 936, Department of Economics and Business, Universitat Pompeu Fabra.
- Beatriz Domínguez & Juan-José Ganuza & Gerard Llobet, 2006. "R&D in the Pharmaceutical Industry: A World of Small Innovations," Working Papers wp2006_0601, CEMFI.
- Bradley T. Shapiro, 2016. "Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR," Quantitative Marketing and Economics (QME), Springer, vol. 14(3), pages 201-231, September.
- Peter Grajzl & Stjepan Srhoj & Jaka Cepec & Barbara Mörec, 2024. "A by-product of big government: the attenuating role of public procurement for the effectiveness of grants-based entrepreneurship policy," Small Business Economics, Springer, vol. 62(3), pages 895-916, March.
- Antonio Cabrales & Sergi Jiménez‐Martín, 2013.
"The Determinants Of Pricing In Pharmaceuticals: Are Us Prices Really So High?,"
Health Economics, John Wiley & Sons, Ltd., vol. 22(11), pages 1377-1397, November.
- Antonio Cabrales & Sergi Jiménez-Martín, 2008. "The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really so high?," Working Papers 2008-18, FEDEA.
- Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2012. "In Whom We Trust: The Role of Certification Agencies in Online Drug Markets," NBER Working Papers 17955, National Bureau of Economic Research, Inc.
- Ernst R. Berndt & Joseph P. Newhouse, 2010.
"Pricing and Reimbursement in U.S. Pharmaceutical Markets,"
NBER Working Papers
16297, National Bureau of Economic Research, Inc.
- Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
- Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
- Kyna Fong & Michael Schwarz, 2009. "Towards an Efficient Mechanism for Prescription Drug Procurement," NBER Working Papers 14718, National Bureau of Economic Research, Inc.
- Clemens, Jeffrey & Gottlieb, Joshua D. & Molnár, Tímea Laura, 2017. "Do health insurers innovate? Evidence from the anatomy of physician payments," Journal of Health Economics, Elsevier, vol. 55(C), pages 153-167.
- Oriana Bandiera & Michael Carlos Best & Adnan Qadir Khan & Andrea Prat, 2021.
"The Allocation of Authority in Organizations: A Field Experiment with Bureaucrats,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 136(4), pages 2195-2242.
- Best, Michael & Bandiera, Oriana & Khan, Adnan & Prat, Andrea, 2020. "The Allocation of Authority in Organizations: A Field Experiment with Bureaucrats," CEPR Discussion Papers 14381, C.E.P.R. Discussion Papers.
- Oriana Bandiera & Michael Carlos Best & Adnan Qadir Khan & Andrea Prat, 2020. "The Allocation of Authority in Organizations: A Field Experiment with Bureaucrats," NBER Working Papers 26733, National Bureau of Economic Research, Inc.
- Bandiera, Oriana & Best, Michael Carlos & Khan, Adnan & Prat, Andrea, 2021. "The allocation of authority in organizations: a field experiment with bureaucrats," LSE Research Online Documents on Economics 111840, London School of Economics and Political Science, LSE Library.
- Steve Cicala & Ethan M.J. Lieber & Victoria Marone, 2017. "Cost of Service Regulation in U.S. Health Care: Minimum Medical Loss Ratios," NBER Working Papers 23353, National Bureau of Economic Research, Inc.
- Marianne P. Bitler & Madeline Zavodny, 2014. "Medicaid: A Review of the Literature," NBER Working Papers 20169, National Bureau of Economic Research, Inc.
- Arvate, Paulo Roberto & Barbosa, Klênio & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, FGV EESP - Escola de Economia de São Paulo, Fundação Getulio Vargas (Brazil).
- Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
- Mark G. Duggan & Fiona Scott Morton, 2011. "The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices," American Economic Review, American Economic Association, vol. 101(3), pages 387-392, May.
- Baker, Laurence C. & Bundorf, M. Kate & Kessler, Daniel P., 2015. "Does health plan generosity enhance hospital market power?," Journal of Health Economics, Elsevier, vol. 44(C), pages 54-62.
- Jena, Anupam B. & Philipson, Tomas J., 2013.
"Endogenous cost-effectiveness analysis and health care technology adoption,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
- Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.
- Katherine Meckel, 2020.
"Is the Cure Worse Than the Disease? Unintended Effects of Payment Reform in a Quantity-Based Transfer Program,"
American Economic Review, American Economic Association, vol. 110(6), pages 1821-1865, June.
- Katherine Meckel, 2020. "Is the Cure Worse than the Disease? Unintended Effects of Payment Reform in a Quantity-based Transfer Program," NBER Working Papers 26725, National Bureau of Economic Research, Inc.
- Jihui Chen, 2019. "The Effects of Competition on Prescription Payments in Retail Pharmacy Markets," Southern Economic Journal, John Wiley & Sons, vol. 85(3), pages 865-898, January.
- Matthew Grennan & Ashley Swanson, 2020.
"Transparency and Negotiated Prices: The Value of Information in Hospital-Supplier Bargaining,"
Journal of Political Economy, University of Chicago Press, vol. 128(4), pages 1234-1268.
- Matthew Grennan & Ashley Swanson, 2016. "Transparency and Negotiated Prices: The Value of Information in Hospital-Supplier Bargaining," NBER Working Papers 22039, National Bureau of Economic Research, Inc.
- Andrew L. Hicks & Ernst R. Berndt & Richard G. Frank, 2024. "Auditing the prescription drug consumer price index in a changing marketplace," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1793-1810, August.
- Steve Cicala & Ethan M. J. Lieber & Victoria Marone, 2019. "Regulating Markups in US Health Insurance," American Economic Journal: Applied Economics, American Economic Association, vol. 11(4), pages 71-104, October.
- Newham, Melissa & Valente, Marica, 2024.
"The cost of influence: How gifts to physicians shape prescriptions and drug costs,"
Journal of Health Economics, Elsevier, vol. 95(C).
- Melissa Newham & Marica Valente, 2022. "The Cost of Influence: How Gifts to Physicians Shape Prescriptions and Drug Costs," Papers 2203.01778, arXiv.org, revised Apr 2023.
- Melissa Newham & Marica Valente, 2023. "The Cost of Influence:How Gifts to Physicians Shape Prescriptions and Drug Costs," Working Papers 2023-03, Faculty of Economics and Statistics, Universität Innsbruck.
- Cheung, Cherry & Coucke, Kristien & Neicu, Daniel, 2011. "A Decision Tree as a Quick Scan for Effective Market Functioning," Working Papers 2011/06, Hogeschool-Universiteit Brussel, Faculteit Economie en Management.
- Mark Duggan & Patrick Healy & Fiona Scott Morton, 2008. "Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D," Journal of Economic Perspectives, American Economic Association, vol. 22(4), pages 69-92, Fall.
- Stamm, Andreas & Dietrich, Luise & Harling, Heike & Häußler, Laura & Münch, Florian & Preiß, Jana & Siebert, Jan, 2019. "Sustainable public procurement as a tool to foster sustainable development in Costa Rica: Challenges and recommendations for policy implementation," IDOS Studies, German Institute of Development and Sustainability (IDOS), volume 100, number 100, July.
- Leemore Dafny & David Dranove, 2006. "Regulatory Exploitation and the Market for Corporate Controls," NBER Working Papers 12438, National Bureau of Economic Research, Inc.
- Lakdawalla, Darius & Sood, Neeraj, 2009. "Innovation and the welfare effects of public drug insurance," Journal of Public Economics, Elsevier, vol. 93(3-4), pages 541-548, April.
- Nancy L. Rose, 2014. "Learning from the Past: Insights for the Regulation of Economic Activity," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 1-23, National Bureau of Economic Research, Inc.
- Collins, J. Michael & Simon, Kosali I. & Tennyson, Sharon, 2013. "Drug withdrawals and the utilization of therapeutic substitutes: The case of Vioxx," Journal of Economic Behavior & Organization, Elsevier, vol. 86(C), pages 148-168.
- Ridley, David B. & Zhang, Su, 2017. "Regulation of price increases," International Journal of Industrial Organization, Elsevier, vol. 50(C), pages 186-213.
- David B. Ridley & Chung-Ying Lee, 2020. "Does Medicare Reimbursement Drive Up Drug Launch Prices?," The Review of Economics and Statistics, MIT Press, vol. 102(5), pages 980-993, December.
- Ulrich Doraszelski & Katja Seim & Michael Sinkinson & Peichun Wang, 2017. "Ownership Concentration and Strategic Supply Reduction," NBER Working Papers 23034, National Bureau of Economic Research, Inc.
- Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
- Bate Roger & Jin Ginger Zhe & Mathur Aparna, 2013. "In Whom We Trust: The Role of Certification Agencies in Online Drug Markets," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 14(1), pages 111-150, December.
- Kaufmann, Cornel & Schmid, Christian & Boes, Stefan, 2017. "Health insurance subsidies and deductible choice: Evidence from regional variation in subsidy schemes," Journal of Health Economics, Elsevier, vol. 55(C), pages 262-273.
- Francesco Decarolis & Maria Polyakova & Stephen P. Ryan, 2020.
"Subsidy Design in Privately Provided Social Insurance: Lessons from Medicare Part D,"
Journal of Political Economy, University of Chicago Press, vol. 128(5), pages 1712-1752.
- Francesco Decarolis & Maria Polyakova & Stephen P. Ryan, 2015. "Subsidy Design in Privately-Provided Social Insurance: Lessons from Medicare Part D," NBER Working Papers 21298, National Bureau of Economic Research, Inc.
- Duggan, Mark, 2005. "Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics," Journal of Health Economics, Elsevier, vol. 24(1), pages 1-31, January.
- Alpert, Abby & Duggan, Mark & Hellerstein, Judith K., 2013.
"Perverse reverse price competition: Average wholesale prices and Medicaid pharmaceutical spending,"
Journal of Public Economics, Elsevier, vol. 108(C), pages 44-62.
- Abby Alpert & Mark Duggan & Judith K. Hellerstein, 2013. "Perverse Reverse Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical Spending," NBER Working Papers 19367, National Bureau of Economic Research, Inc.
- Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo, 2017. "Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015," PharmacoEconomics - Open, Springer, vol. 1(2), pages 123-131, June.
- Darius Lakdawalla & Wesley Yin, 2015.
"Insurers’ Negotiating Leverage and the External Effects of Medicare Part D,"
The Review of Economics and Statistics, MIT Press, vol. 97(2), pages 314-331, May.
- Darius N. Lakdawalla & Wesley Yin, 2010. "Insurers' Negotiating Leverage and the External Effects of Medicare Part D," NBER Working Papers 16251, National Bureau of Economic Research, Inc.
- Wesley Yin & Darius Lakdawalla, 2011. "Insurers’ Negotiating Leverage and the External Effects of Medicare Part D," Boston University - Department of Economics - Working Papers Series WP2011-065, Boston University - Department of Economics.
- García-Alonso, M. D. C. & Mariñoso, B. G., 2005. "The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations," Working Papers 05/02, Department of Economics, City University London.
- Kyle Margaret, 2011.
"Strategic Responses to Parallel Trade,"
The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 11(2), pages 1-34, January.
- Margaret K. Kyle, 2007. "Strategic Responses to Parallel Trade," NBER Working Papers 12968, National Bureau of Economic Research, Inc.
- Cabiedes Miragaya, Laura, 2013. "Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 31, pages 397-416, Septiembr.
- Jonathan Gruber, 2017. "Delivering Public Health Insurance through Private Plan Choice in the United States," Journal of Economic Perspectives, American Economic Association, vol. 31(4), pages 3-22, Fall.
- Mark Duggan & Fiona Scott Morton, 2010.
"The Effect of Medicare Part D on Pharmaceutical Prices and Utilization,"
American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.
- Mark Duggan & Fiona Scott Morton, 2008. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," NBER Working Papers 13917, National Bureau of Economic Research, Inc.
- SUN Jessica Ya & YIN Ting & LIU Zhiyong, 2023. "When State Becomes the Only Buyer: Effects of national volume-based procurement of cardiac stents in China," Discussion papers 23065, Research Institute of Economy, Trade and Industry (RIETI).
- Laurence C. Baker & M. Kate Bundorf & Daniel P. Kessler, 2015. "Does Health Plan Generosity Enhance Hospital Market Power?," NBER Working Papers 21513, National Bureau of Economic Research, Inc.
- Claudio Lucarelli & Sean Nicholson & Minjae Song, 2010. "Bundling Among Rivals: A Case of Pharmaceutical Cocktails," NBER Working Papers 16321, National Bureau of Economic Research, Inc.
- Robin McKnight & Jonathan Reuter & Eric Zitzewitz, 2012. "Insurance as Delegated Purchasing: Theory and Evidence from Health Care," NBER Working Papers 17857, National Bureau of Economic Research, Inc.
- Bergman, Mats & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," HUI Working Papers 116, HUI Research.
- Leemore Dafny & David Dranove, 2009. "Regulatory Exploitation and Management Changes: Upcoding in the Hospital Industry," Journal of Law and Economics, University of Chicago Press, vol. 52(2), pages 223-250, May.
- Doraszelski, Ulrich & , & Sinkinson, Michael & Wang, Peichun, 2016. "Ownership Concentration and Strategic Supply Reduction," CEPR Discussion Papers 11173, C.E.P.R. Discussion Papers.
- Clark, Robert & Fabiilli, Christopher & Lasio, Laura, 2022.
"Collusion in the US generic drug industry,"
International Journal of Industrial Organization, Elsevier, vol. 85(C).
- Robert Clark & Christopher Anthony Fabiilli & Laura Lasio, 2021. "Collusion in the US Generic Drug Industry," Working Paper 1474, Economics Department, Queen's University.
- Jurjen Kamphorst & Vladimir Karamychev, 2021. "Going Through The Roof: On Prices for Drugs Sold Through Insurance," Tinbergen Institute Discussion Papers 21-005/VII, Tinbergen Institute.
- Xu, Sha & Wu, Dejun, 2023. "Centralized Drug Procurement and asymmetric earnings management: Evidence from China," Finance Research Letters, Elsevier, vol. 58(PA).
- Aidan R. Vining, 2016. "What Is Public Agency Strategic Analysis (PASA) and How Does It Differ from Public Policy Analysis and Firm Strategy Analysis?," Administrative Sciences, MDPI, vol. 6(4), pages 1-31, December.
- Decarolis, Francesco, 2015. "The unintended effects of the Medicare Part D low income subsidy," Health Policy, Elsevier, vol. 119(5), pages 597-603.
- Matthew Grennan, 2013. "Price Discrimination and Bargaining: Empirical Evidence from Medical Devices," American Economic Review, American Economic Association, vol. 103(1), pages 145-177, February.
- Riccaboni, Massimo & Swoboda, Torben & Van Dyck, Walter, 2022. "Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model," Health Policy, Elsevier, vol. 126(6), pages 534-540.
- Robert G. Valletta, 2007. "The costs and value of new medical technologies: symposium summary," FRBSF Economic Letter, Federal Reserve Bank of San Francisco, issue jul6.
- Kotsios, Panayotis, 2010. "Regulatory Barriers to Entry in Industrial Sectors," MPRA Paper 27976, University Library of Munich, Germany.